Post-HTS case report and structural alert: Promiscuous 4-aroyl-1,5-disubstituted-3-hydroxy-2H-pyrrol-2-one actives verified by ALARM NMR

Jayme L. Dahlin; J. Willem M. Nissink; Subhashree Francis; Jessica M. Strasser; Kristen John; Zhiguo Zhang; Michael A. Walters

doi:10.1016/j.bmcl.2015.08.020

Post-HTS case report and structural alert: Promiscuous 4-aroyl-1,5-disubstituted-3-hydroxy-2H-pyrrol-2-one actives verified by ALARM NMR

Jayme L. Dahlin, J. Willem M. Nissink, Subhashree Francis, Jessica M. Strasser, Kristen John, Zhiguo Zhang, Michael A. Walters

Institute for Therapeutics Discovery and Development

Research output: Contribution to journal › Article › peer-review

13 Scopus citations

Abstract

Despite its wide use, not every high-throughput screen (HTS) yields chemical matter suitable for drug development campaigns, and seldom are 'go/no-go' decisions in drug discovery described in detail. This case report describes the follow-up of a 4-aroyl-1,5-disubstituted-3-hydroxy-2H-pyrrol-2-one active from a cell-free HTS to identify small-molecule inhibitors of Rtt109-catalyzed histone acetylation. While this compound and structural analogs inhibited Rtt109-catalyzed histone acetylation in vitro, further work on this series was halted after several risk mitigation strategies were performed. Compounds with this chemotype had a poor structure-activity relationship, exhibited poor selectivity among other histone acetyltransferases, and tested positive in a β-lactamase counter-screen for chemical aggregates. Furthermore, ALARM NMR demonstrated compounds with this chemotype grossly perturbed the conformation of the La protein. In retrospect, this chemotype was flagged as a 'frequent hitter' in an analysis of a large corporate screening deck, yet similar compounds have been published as screening actives or chemical probes versus unrelated biological targets. This report - including the decision-making process behind the 'no-go' decision - should be informative for groups engaged in post-HTS triage and highlight the importance of considering physicochemical properties in early drug discovery.

Original language	English (US)
Pages (from-to)	4740-4752
Number of pages	13
Journal	Bioorganic and Medicinal Chemistry Letters
Volume	25
Issue number	21
DOIs	https://doi.org/10.1016/j.bmcl.2015.08.020
State	Published - Nov 1 2015

Bibliographical note

Funding Information:
This work was supported by the Minnesota Partnership for Biotechnology and Medical Genomics ( 73-01 to M.A.W. and Z.Z.), the NIH ( GM72719 and GM81838 to Z.Z.), the Mayo Foundation for Medical Education and Research and the Minnesota Supercomputing Institute. J.L.D. was supported by an NIH predoctoral fellowship (F30 DK092026-01), a Pharmaceutical Research and Manufacturers of America Foundation predoctoral pharmacology/toxicology fellowship and the Mayo Foundation. Funding for NMR instrumentation was provided by the Office of the Vice President for Research, the University of Minnesota Medical School, the University of Minnesota College of Biological Science, the NIH, the NSF and the Minnesota Medical Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The opinions or assertions contained herein belong to the authors and are not necessarily the official views of the funders.

Publisher Copyright:
© 2015 Elsevier Ltd. All rights reserved.

Keywords

Chemical aggregation
Drug discovery
High-throughput screening
PAINS
Pan-assay interference compounds
Structureactivity relationships

Access

10.1016/j.bmcl.2015.08.020

OpenUrl availability

Full text

Cite this

@article{b4203d86e20444d3a345d09ad5d03917,

title = "Post-HTS case report and structural alert: Promiscuous 4-aroyl-1,5-disubstituted-3-hydroxy-2H-pyrrol-2-one actives verified by ALARM NMR",

abstract = "Despite its wide use, not every high-throughput screen (HTS) yields chemical matter suitable for drug development campaigns, and seldom are 'go/no-go' decisions in drug discovery described in detail. This case report describes the follow-up of a 4-aroyl-1,5-disubstituted-3-hydroxy-2H-pyrrol-2-one active from a cell-free HTS to identify small-molecule inhibitors of Rtt109-catalyzed histone acetylation. While this compound and structural analogs inhibited Rtt109-catalyzed histone acetylation in vitro, further work on this series was halted after several risk mitigation strategies were performed. Compounds with this chemotype had a poor structure-activity relationship, exhibited poor selectivity among other histone acetyltransferases, and tested positive in a β-lactamase counter-screen for chemical aggregates. Furthermore, ALARM NMR demonstrated compounds with this chemotype grossly perturbed the conformation of the La protein. In retrospect, this chemotype was flagged as a 'frequent hitter' in an analysis of a large corporate screening deck, yet similar compounds have been published as screening actives or chemical probes versus unrelated biological targets. This report - including the decision-making process behind the 'no-go' decision - should be informative for groups engaged in post-HTS triage and highlight the importance of considering physicochemical properties in early drug discovery.",

keywords = "Chemical aggregation, Drug discovery, High-throughput screening, PAINS, Pan-assay interference compounds, Structureactivity relationships",

author = "Dahlin, {Jayme L.} and Nissink, {J. Willem M.} and Subhashree Francis and Strasser, {Jessica M.} and Kristen John and Zhiguo Zhang and Walters, {Michael A.}",

note = "Funding Information: This work was supported by the Minnesota Partnership for Biotechnology and Medical Genomics ( 73-01 to M.A.W. and Z.Z.), the NIH ( GM72719 and GM81838 to Z.Z.), the Mayo Foundation for Medical Education and Research and the Minnesota Supercomputing Institute. J.L.D. was supported by an NIH predoctoral fellowship (F30 DK092026-01), a Pharmaceutical Research and Manufacturers of America Foundation predoctoral pharmacology/toxicology fellowship and the Mayo Foundation. Funding for NMR instrumentation was provided by the Office of the Vice President for Research, the University of Minnesota Medical School, the University of Minnesota College of Biological Science, the NIH, the NSF and the Minnesota Medical Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The opinions or assertions contained herein belong to the authors and are not necessarily the official views of the funders. Publisher Copyright: {\textcopyright} 2015 Elsevier Ltd. All rights reserved.",

year = "2015",

month = nov,

day = "1",

doi = "10.1016/j.bmcl.2015.08.020",

language = "English (US)",

volume = "25",

pages = "4740--4752",

journal = "Bioorganic and Medicinal Chemistry Letters",

issn = "0960-894X",

publisher = "Elsevier Limited",

number = "21",

}

TY - JOUR

T1 - Post-HTS case report and structural alert

T2 - Promiscuous 4-aroyl-1,5-disubstituted-3-hydroxy-2H-pyrrol-2-one actives verified by ALARM NMR

AU - Dahlin, Jayme L.

AU - Nissink, J. Willem M.

AU - Francis, Subhashree

AU - Strasser, Jessica M.

AU - John, Kristen

AU - Zhang, Zhiguo

AU - Walters, Michael A.

N1 - Funding Information: This work was supported by the Minnesota Partnership for Biotechnology and Medical Genomics ( 73-01 to M.A.W. and Z.Z.), the NIH ( GM72719 and GM81838 to Z.Z.), the Mayo Foundation for Medical Education and Research and the Minnesota Supercomputing Institute. J.L.D. was supported by an NIH predoctoral fellowship (F30 DK092026-01), a Pharmaceutical Research and Manufacturers of America Foundation predoctoral pharmacology/toxicology fellowship and the Mayo Foundation. Funding for NMR instrumentation was provided by the Office of the Vice President for Research, the University of Minnesota Medical School, the University of Minnesota College of Biological Science, the NIH, the NSF and the Minnesota Medical Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The opinions or assertions contained herein belong to the authors and are not necessarily the official views of the funders. Publisher Copyright: © 2015 Elsevier Ltd. All rights reserved.

PY - 2015/11/1

Y1 - 2015/11/1

N2 - Despite its wide use, not every high-throughput screen (HTS) yields chemical matter suitable for drug development campaigns, and seldom are 'go/no-go' decisions in drug discovery described in detail. This case report describes the follow-up of a 4-aroyl-1,5-disubstituted-3-hydroxy-2H-pyrrol-2-one active from a cell-free HTS to identify small-molecule inhibitors of Rtt109-catalyzed histone acetylation. While this compound and structural analogs inhibited Rtt109-catalyzed histone acetylation in vitro, further work on this series was halted after several risk mitigation strategies were performed. Compounds with this chemotype had a poor structure-activity relationship, exhibited poor selectivity among other histone acetyltransferases, and tested positive in a β-lactamase counter-screen for chemical aggregates. Furthermore, ALARM NMR demonstrated compounds with this chemotype grossly perturbed the conformation of the La protein. In retrospect, this chemotype was flagged as a 'frequent hitter' in an analysis of a large corporate screening deck, yet similar compounds have been published as screening actives or chemical probes versus unrelated biological targets. This report - including the decision-making process behind the 'no-go' decision - should be informative for groups engaged in post-HTS triage and highlight the importance of considering physicochemical properties in early drug discovery.

AB - Despite its wide use, not every high-throughput screen (HTS) yields chemical matter suitable for drug development campaigns, and seldom are 'go/no-go' decisions in drug discovery described in detail. This case report describes the follow-up of a 4-aroyl-1,5-disubstituted-3-hydroxy-2H-pyrrol-2-one active from a cell-free HTS to identify small-molecule inhibitors of Rtt109-catalyzed histone acetylation. While this compound and structural analogs inhibited Rtt109-catalyzed histone acetylation in vitro, further work on this series was halted after several risk mitigation strategies were performed. Compounds with this chemotype had a poor structure-activity relationship, exhibited poor selectivity among other histone acetyltransferases, and tested positive in a β-lactamase counter-screen for chemical aggregates. Furthermore, ALARM NMR demonstrated compounds with this chemotype grossly perturbed the conformation of the La protein. In retrospect, this chemotype was flagged as a 'frequent hitter' in an analysis of a large corporate screening deck, yet similar compounds have been published as screening actives or chemical probes versus unrelated biological targets. This report - including the decision-making process behind the 'no-go' decision - should be informative for groups engaged in post-HTS triage and highlight the importance of considering physicochemical properties in early drug discovery.

KW - Chemical aggregation

KW - Drug discovery

KW - High-throughput screening

KW - PAINS

KW - Pan-assay interference compounds

KW - Structureactivity relationships

UR - http://www.scopus.com/inward/record.url?scp=84944151490&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944151490&partnerID=8YFLogxK

U2 - 10.1016/j.bmcl.2015.08.020

DO - 10.1016/j.bmcl.2015.08.020

M3 - Article

C2 - 26318992

AN - SCOPUS:84944151490

SN - 0960-894X

VL - 25

SP - 4740

EP - 4752

JO - Bioorganic and Medicinal Chemistry Letters

JF - Bioorganic and Medicinal Chemistry Letters

IS - 21

ER -

Post-HTS case report and structural alert: Promiscuous 4-aroyl-1,5-disubstituted-3-hydroxy-2H-pyrrol-2-one actives verified by ALARM NMR

Abstract

Bibliographical note

Keywords

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this